Grifols says its anti-COVID-19 therapeutics ready for trials

Tuesday, 28. July 2020 16:58

Grifols announced on Tuesday that it started delivering manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials.

The therapeutics target the virus behind COVID-19 by giving passive immunity to patients by using convalescent plasma from people who have recovered from the coronavirus. Grifols added that the treatment could be used both as a COVID-19 treatment and prevention. Clinical trials are expected to start in both the United States and Europe soon.

“Grifols is grateful to all the plasma donors who through their generosity are now helping to develop a medicine, a hyperimmune globulin, whose concentrated antibodies will potentially provide others with passive immunity to overcome the disease,” co-CEO of Grifols Victor Grifols Deu (pictured right) said.

Related Links: Grifols S.A.
Author:
Breaking the News / VP